Mon 20 Dec 21 5% Gain

 

Mon 20 Dec 21

QDEL [NASD]

Quidel Corporation

Healthcare | Diagnostics & Research | USA looking for Gap to fill and come back for Buy at 160 Possible 150 buy or 150 stop loss News ...plays to the strength of Quidel in the coronavirus testing segment, as top-down testing and vaccination mandates either remain in force or are introduced by entities that hadn't previously required them. Also, the level of personal fear is rising along with those escalating numbers. As a result, many people not covered by mandates are willingly submitting to COVID tests. Now what COVID testing is the motor driving Quidel's success just now. In the healthcare company's third-quarter, which occurred amid the spread of the delta variant, such diagnostics comprised nearly 80% of revenue (which, incidentally, rose by 7% year over year in total). As long as the coronavirus -- whichever variant happens to be raging at the moment -- is on a rampage, the company should continue to do well. ------------------------------------- FLGT [NASD] Fulgent Genetics, Inc. Healthcare | Diagnostics & Research | USA Look at this to retrace back to the trend line or 100 for a buy? Fulgent Genetics, Inc. FLGT: This company that provides COVID-19 testing and genetic testing services has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 26.7% over the last 60 days. oby Bordelon: We have another question that's got a lot of votes from Mike. He asked, Fulgent Genetics was down 10% today and he wants to know if that was due to the announcement of research data on the COVID pill from Pfizer (NYSE:PFE) which I guess came out today. Do you have any thoughts on this, Rachel? I know you follow the healthcare industry a little bit. Rachel Warren: Yeah. I like Fulgent Genetics, I think they're a great company. I think it's possible. I was looking at, for example, Moderna (NASDAQ:MRNA) stock. Moderna was down about 17% today, which is a bit of a jump, but it's just one day. I think that's very much possible, although just for context, shares of Fulgent have been falling a little bit recently. The company is strong, the business is strong, it rose to the forefront of investors' attention I think because of the variety of COVID-19 tests released. But it does have a really robust portfolio of other tests that are contributing more and more to its overall revenue and driving really strong balance sheet growth. I think it could be a range of factors. I think there's been an overall concern among some investors about a long-term need for some of these tests as you have more therapeutics introduced. Then of course with the news today from Pfizer. I would say just at first glance because I've been reading up about this, it's a combination of things. But at the moment, it doesn't change my personal take on this company. I really like this company. I believe it reports its third-quarter earnings next week. I'll keep an eye on those to see what happens after that. --------------------------------------- LLNW [NASD] Limelight Networks, Inc. Technology | Software - Infrastructure | USA Looking for a retrace back to 3.40 Key Points Raymond James says that Limelight is a strong buy right now with a 40% upside. The company is executing an ambitious growth strategy. Motley Fool Issues Rare “All In” Buy Alert What happened Shares of Limelight Networks (NASDAQ:LLNW) jumped as much as 12.7% higher on Monday morning thanks to a bullish analyst report. By 11 a.m. ET, the content delivery network (CDN) specialist's stock had cooled down somewhat to a 9% gain. So what According to Raymond James analyst Frank Louthan, Limelight is executing "a solid transition" to boost the company's product portfolio and expand the addressable target market. Given it has a year or so to continue this expansion, Louthan expects Limelight to report higher sales while the stock should earn higher valuation ratios. All told, the analyst sees this stock as a strong buy at current prices. Louthan's price target of $5 per share represents a 40% upside compared with last Friday's closing price. SCOTTSDALE, Ariz., Dec. 15, 2021 /PRNewswire/ -- Limelight Networks, Inc. (Nasdaq: LLNW), a leading provider of content delivery services and AppOps at the edge, today announced general availability of GraphQL functionality for its Layer0 by Limelight web application CDN. GraphQL is an important enabler of microservices-based (aka headless) websites, allowing web builders to make their API layer much faster and easier to manage. Layer0 has solved the key challenge of caching GraphQL APIs at the network edge, which is not supported by traditional web CDNs. In addition, the solution supports hosting the GraphQL server in a serverless environment. These new capabilities enhance Limelight's presence in the $4.4 billion web application CDN market, especially as web builders, not the operations team, are driving these purchase decisions. ------------------------------ Based on Finviz settings ::